A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

OMIP-022: Comprehensive assessment of antigen-specific human T-cell functionality and memory

(2014) Andrew J. Graves et al.   CYTOMETRY PART A

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial

(2014) Iman Satti et al.   LANCET INFECTIOUS DISEASES

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

(2012) Daniel F. Hoft et al.   VACCINE

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery

(2012) Joel Meyer et al.   VACCINE

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults

(2012) Rosalind Rowland et al.   Human Vaccines & Immunotherapeutics

The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+and CD8+T Cells in Adults

(2010) Brian Abel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis

(2009) Liliana Encinales et al.   MOLECULAR IMMUNOLOGY

Early T-cell responses in tuberculosis immunity

(2008) Gary M. Winslow et al.   IMMUNOLOGICAL REVIEWS